Metrebian, Nicola
Carter, Ben
Eide, Desiree
McDonald, Rebecca
Neale, Joanne
Parkin, Stephen
Dascal, Teodora
Mackie, Clare
Day, Ed
Guterstam, Joar
Horsburgh, Kirsten
Kåberg, Martin
Kelleher, Mike
Smith, Josie
Thiesen, Henrik
Strang, John http://orcid.org/0000-0002-5413-2725
Funding for this research was provided by:
Mundipharma Research Limited
Article History
Received: 28 September 2022
Accepted: 2 August 2023
First Online: 24 August 2023
Declarations
:
: This study received NHS Research Ethics Committee approval on 25th June 2020 from North-East Newcastle & North Tyneside Research Ethics Committee (20/NE/0131) (with approval for a Substantial Amendment on 19th March 2021). Consent will be obtained from individuals to whom take home naloxone has been supplied and who are eligible for the study. Additional consent will be sought from participants who use drugs, to use their personal data for linkage to the national/regional death registers to identify any deaths during the study period.
: Not applicable.
: This study has funding support from Mundipharma Research Limited, a pharmaceutical company who have developed and market a concentrated naloxone nasal-spray.Ben Carter: received, through his university research funding from Mundipharma Research Ltd. Desiree Eide: DE has no competing interests.Teodora Dascal: no competing interestsEd Day: no competing interestsJoar Guterstam: no competing interestsKirsten Horsburgh: no competing interests.Mike Kelleher: in the past 3 years, has taken part in research funded by Indivior, Camurus and Mundipharma. He has received honoraria from Indivior, Gilead, and Abbvie.Martin Kåberg: received honoraria for lectures/consultancy from Abbvie, Gilead, MSD, Mundipharma, DnE Pharma, and Nordic Drugs and has received research grants from Gilead and Nordic Drugs.Clare Mackie: no competing interestsRebecca McDonald: indirectly received, through her former employer King’s College London, funding from Mundipharma Research Ltd that supported her position of employment (2019–21). RM was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London.Nicola Metrebian: received, through her university, King’s College London, research funding from Mundipharma Research Ltd (pharmaceutical company that produces a naloxone nasal spray). She has also received, through her university, consultancy payment from an agency for Mayne Pharma International, on another area of research not relevant to the article under consideration.Joanne Neale: received, through her university, research funding from Mundipharma Research Ltd and Camurus AB for unrelated research and an honorarium from Indivior for an unrelated conference presentation. JN was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London.Stephen Parkin: received funding, as part of his employment within King’s College London, funding from Mundipharma Research Ltd, and Camurus AB pharmaceutical company and The Pilgrim Trust. SP was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London.Josie Smith: no competing interests.John Strang: longstanding advocate for, and research enquirer into, take-home naloxone. Through his university, JS has worked/is working with pharma and tech industries to identify new or improved interventions (including overdose crisis management) and his employer (King’s College London) has received grants, travel costs and/or consultancy payments; this includes discussion and investigation of new naloxone formulations with, past 3 years, Mundipharma, Accord, dne pharma (all of whom have naloxone products). JS is currently leading a cohort study of individuals to whom a supply of takehome naloxone has been provided and who are being followed up prospectively over time, supported by an investigator-initiated grant from Mundipharma. His employer (King’s College London) also earlier registered intellectual property on a buccal naloxone formulation, naming JS and colleagues, and he was previously named in a patent registration by a pharmaceutical company regarding concentrated nasal naloxone spray. JS does not receive any personal payment from these arrangements. JS was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. For a fuller account, see JS’s web-page at ExternalRef removedHenrik Thiesen: no competing interests